Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. has demonstrated a notable increase in Research and Development (R&D) expenses, reflecting a commitment to advancing its product candidates, with expenses rising by 21% year-over-year to $14.0 million and projected to reach $58.2 million in 2025, a 36% increase from the prior year. Furthermore, the company's Selling, General & Administrative (SG&A) expenses also experienced growth, increasing by 12% to $26.9 million, indicative of an investment in operational capabilities that support its strategic goals. The reliance on commercial partners to penetrate target markets and increase sales of its innovative medical technologies positions the company for potential revenue growth as these partnerships evolve.

Bears say

Orchestra BioMed Holdings Inc. has faced ongoing operating losses since its inception, reflecting its status as a development-stage company. The persistent history of losses raises concerns about the company's ability to achieve and maintain profitability in the future. Additionally, these financial challenges could hinder the company's long-term growth prospects and investor confidence in its product candidates.

OBIO has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 4 analysts, OBIO has a Strong Buy consensus rating as of Apr 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.